Epizyme stock: buy or sell?
October 18th, 2019
Epizyme, Inc., a clinical stage biopharmaceutical company, discovers and develops novel epigenetic therapies for patients with cancer and other diseases in the United States.
Should I buy Epizyme stock?Make a decision about when to buy or sell stocks is one of the hardest parts of being a trader or investor. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Epizyme stock situation right now, therefore this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Epizyme stock a buy?
Everyday, hundreds of stock ratings are published by financial analysts to indicate a particular stock's attractiveness.At Stocks2.com, we detected 6 ratings published for EPZM stock in the last month. The general sentiment of these ratings is bullish for EPZM stock, with 6 positive ratings.
|Date||Analyst / Broker||Previous rating||Current rating|
|2019-1-7||Leerink Swann||Market Perform||Outperform|
Epizyme stock analysis
Shares of Epizyme declined a lame -1.24% and closed at $10.34.
Epizyme shares declined -1.24% to $10.34 on Oct 18th. Since price and SMA200d lines crossed down on September/19, EPZM fell $-1.40 per share (-11.93%).
After sliding a hair-raising -8.47% in a week last week, Epizyme closed this week at $10.34 and escalated a pretty good 3.09%. Late September EPZM rocketed an extraordinary 6.53% in just one week.
Since mid September, when EPZM stock price broke down the 40-weeks moving avarage line, it slid $-1.62 per share (-13.55%). Trading stocks that are under the 40-weeks (that is, 200-days) moving average mark is not recommended by many experts, as it indicates that the stock has not enough institutional support. Since SMA20w and SMA40w crossed up early April, EPZM price slid a -24.19%.
Epizyme stock price history
Epizyme stock went public on May 31st, 2013 with a price of $20.001. Since then, EPZM stock declined a -48.30%, with a yearly average of -8.10%.
1: Adjusted price after possible price splits or reverse-splits.
Epizyme stock historical price chart
EPZM stock reached 52-week highs on June at $16.59, and all-time highs 2013-07-17 with a price of 45.72.
Epizyme stock price target is $20.50Nobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. We do not recommend to follow these stock price predictions without a critical thinking from your side, as their accuracy is usually low. For the last 30 days we found 4 price targets for EPZM stock:
|Date||Analyst / Broker||Action||Previous target||Current target||Diff|
|2019-6-24||HC Wainwright||Set Price Target||n/a||$25.00||-|
Financials and fundamental analysis
Earnings date and Earnings per ShareOn February, Epizyme missed the expectations of the analysts and reported a bloodcurdling EPS of $-0.29 per share when experts were expecting $-0.49.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an amazing increase of 117.00% to $21.70 million dollars. In line, its earnings margin (compared to sales) rocketed to -569.72%, that is $-123.63 million.
|2013||$68 M||-||$-3.48 M-5.1%||-|
|2014||$41 M||-39.53%||$-55.01 M-132.8%||1,480.60%|
|2015||$2.56 M||-93.82%||$-132.38 M-5170.9%||140.66%|
|2016||$8.01 M||212.77%||$-110.21 M-1376.4%||-16.74%|
|2017||$10 M||24.89%||$-134.31 M-1343.1%||21.86%|
|2018||$22 M||117.00%||$-123.63 M-569.7%||-7.95%|
Quarterly financial resultsEpizyme reported $9.70 million in sales for 2018-Q4, a inf% improvement compared to previous quarter. Reported quarter income marked $-22.95 million with a profit margin of -236.55%. Profit margin stayed constant a 0.00% compared to previous quarter when profit margin was inf%. When comparing sales to same quarter last year, Epizyme sales marked an outstanding growth and skyrocketed a inf%.
|2017-Q2||$10 M||-||$-28.02 M-280.2%||-|
|2018-Q2||$12 M||20.00%||$-29.13 M-242.7%||3.95%|
|2018-Q4||$10 M||-19.17%||$-22.95 M-236.5%||-21.23%|
Epizyme ownershipWhen you are planning to invest in a company, it's always worth to review its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Epizyme, 4.94% of all outstanding shares are owned by its staff.
Bearish positions for EPZM stock account 0.00%, no big difference from last month.
For a better understanding, the following table shows ownership data compared to other related companies:
|Market cap||$941.4 M||$146.5 B||$73.0 B||$13.5 M||$105.9 B|
|Total shares||91.0 M||1,770.0 M||708.7 M||16.7 M||2,490.0 M|
|Float shares||70.5 M||1,750.0 M||706.3 M||13.9 M||2,450.0 M|
|- Institutional holdings (%)||93.2%||76.5%||77.6%||8.1%||11.0%|
|- Insider holdings (%)||4.9%||0.7%||0.2%||16.9%||0.0%|
|Shares in short selling||0.0%||0.0%||0.0%||0.0%||0.0%|
|Friday, October 18th, 2019|
|Day range||$10.29 - $10.55|
|Average true range||$0.48|
|50d mov avg||$11.72|
|100d mov avg||$12.44|
|200d mov avg||$12.15|
Epizyme performanceTo better understand Epizyme performance you must compare its gains with other related stocks in same sector or industry. In the following table, we compare Epizyme to , Celgene, Dare Bioscience, GlaxoSmithKline, Novartis and Seattle Genetics: